CD44v6 as innovative sarcoma target for CAR-redirected CIK cells

References

• Maula S, Huuhtanen RL, Blomqvist CP, Wiklund TA, Laurila P, Ristamäki R. The adhesion molecule CD44v6 is associated with a high risk for local recurrence in adult soft tissue sarcomas. Br J Cancer. 2001;84:244–52. doi:10.1054/bjoc.2000.1590. PMID:11161384.
   PubMed Web of Science ®Google Scholar
• Manten-Horst E, Danen EH, Smit L, Snoek M, Le Poole IC, Van Muijen GN, Pals ST, Ruiter DJ. Expression of CD44 splice variants in human cutaneous melanoma and melanoma cell lines is related to tumor progression and metastatic potential. Int J Cancer 1995;64:182–8. doi:10.1002/ijc.2910640307. PMID:7542641.
   PubMed Web of Science ®Google Scholar
• Kahara N, Ozaki T, Doi T, Nishida K, Kawai A, Shibahara M, et al. CD44 expression in soft tissue sarcomas. Virchows Arch. 2000;436:574–8. doi:10.1007/s004289900159. PMID:10917171.
   PubMed Web of Science ®Google Scholar
• Andritsch E, Beishon M, Bielack S, Bonvalot S, Casali P, Crul M, Delgado Bolton R, Donati DM, Douis H, Haas R, et al. ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review. Crit Rev Oncol Hematol. 2017;110:94–105. doi:10.1016/j.critrevonc.2016.12.002.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat Rev Clin Oncol. 2011;8:577–85. doi:10.1038/nrclinonc.2011.116. PMID:21808266.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29:917–24. doi:10.1200/JCO.2010.32.2537. PMID:21282551.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21:1019–27. doi:10.1158/1078-0432.CCR-14-2708. PMID:25538264.
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993;21:1673–9. PMID:7694868.
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, et al. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 1999;81:1009–16. doi:10.1038/sj.bjc.6690800. PMID:10576658.
   PubMed Web of Science ®Google Scholar
• Gammaitoni L, Giraudo L, Leuci V, Todorovic M, Mesiano G, Picciotto F, Pisacane A, Zaccagna A, Volpe MG, Gallo S, et al. Effective Activity of Cytokine Induced Killer Cells against Autologous Metastatic Melanoma including Cells with Stemness Features. Clin Cancer Res. 2013;19(16):4347–58. doi:10.1158/1078-0432.CCR-13-0061 PMID:23794732.
   PubMed Web of Science ®Google Scholar
• Sangiolo D, Mesiano G, Gammaitoni L, Leuci V, Todorovic M, Giraudo L, Cammarata C, Dell'Aglio C, D'Ambrosio L, Pisacane A, et al. Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. Cancer Res. 2014;74:119–29. doi:10.1158/0008-5472.CAN-13-1559. PMID:24356422.
   PubMed Web of Science ®Google Scholar
• Gammaitoni L, Giraudo L, Macagno M, Leuci V, Mesiano G, Rotolo R, Sassi F, Sanlorenzo M, Zaccagna A, Pisacane A, et al. Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells. Clin Cancer Res. 2017;23:2277–88. doi:10.1158/1078-0432.CCR-16-1524. PMID:27815354.
   PubMed Web of Science ®Google Scholar
• Cappuzzello E, Tosi A, Zanovello P, Sommaggio R, Rosato A. Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies. Oncoimmunology. 2016;5:e1199311. doi:10.1080/2162402X.2016.1199311. PMID:27622068.
   PubMed Web of Science ®Google Scholar
• Olioso P, Giancola R, Di Riti M, Contento A, Accorsi P, Iacone A. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol. 2009. doi:10.1002/hon.886. PMID:19294626.
   PubMed Web of Science ®Google Scholar
• Giraudo L, Gammaitoni L, Cangemi M, Rotolo R, Aglietta M, Sangiolo D. Cytokine-induced killer cells as immunotherapy for solid tumors: current evidences and perspectives. Immunotherapy. 2015;7(9):999–1010. doi:10.2217/imt.15.61. PMID:26310715.
   PubMed Web of Science ®Google Scholar
• Pan K, Guan XX, Li YQ, Zhao JJ, Li JJ, Qiu HJ, Weng DS, Wang QJ, Liu Q, Huang LX, et al. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer. Clin Cancer Res. 2014;20:3003–11. doi:10.1158/1078-0432.CCR-14-0082. PMID:24668644.
   PubMed Web of Science ®Google Scholar
• Schmeel LC, Schmeel FC, Coch C, Schmidt-Wolf IG. Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 2015;141(5):839–49. doi:10.1007/s00432-014-1864-3. PMID:25381063.
   PubMed Web of Science ®Google Scholar
• Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14:123–33. doi:10.1016/S1074-7613(01)00095-4. PMID:11239445.
   PubMed Web of Science ®Google Scholar
• Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A 1999;96:6879–84. doi:10.1073/pnas.96.12.6879. PMID:10359807.
   PubMed Web of Science ®Google Scholar
• Sangiolo D, Martinuzzi E, Todorovic M, Vitaggio K, Vallario A, Jordaney N, Carnevale-Schianca F, Capaldi A, Geuna M, Casorzo L, et al. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol. 2008;20:841–8. doi:10.1093/intimm/dxn042. PMID:18469328.
   PubMed Web of Science ®Google Scholar
• Elia AR, Circosta P, Sangiolo D, Bonini C, Gammaitoni L, Mastaglio S, Genovese P, Geuna M, Avolio F, Inghirami G, et al. Cytokine-induced killer cells engineered with exogenous T-cell receptors directed against melanoma antigens: enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition. Hum Gene Ther. 2015;26:220–31. doi:10.1089/hum.2014.112. PMID:25758764.
   PubMed Web of Science ®Google Scholar
• Leuci V, Mesiano G, Gammaitoni L, Aglietta M, Sangiolo D. Genetically Redirected T Lymphocytes for Adoptive Immunotherapy of Solid Tumors. Curr Gene Ther. 2013.
   Web of Science ®Google Scholar
• Gill S, June CH. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev. 2015;263:68–89. doi:10.1111/imr.12243. PMID:25510272.
   PubMed Web of Science ®Google Scholar
• Dotti G, Savoldo B, Brenner M. Fifteen years of gene therapy based on chimeric antigen receptors: “are we nearly there yet?”. Hum Gene Ther. 2009;20:1229–39. doi:10.1089/hum.2009.142. PMID:19702437.
   PubMed Web of Science ®Google Scholar
• Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993;90:720–4. doi:10.1073/pnas.90.2.720. PMID:8421711.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, et al. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015;33:1688–96. doi:10.1200/JCO.2014.58.0225. PMID:25800760.
   PubMed Web of Science ®Google Scholar
• Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. BiolBlood Marrow Transplant. 2005;11:181–7. doi:10.1016/j.bbmt.2004.11.019.
   PubMed Web of Science ®Google Scholar
• Li R, Wang C, Liu L, Du C, Cao S, Yu J, et al. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother. 2012;61:2125–33. doi:10.1007/s00262-012-1260-2. PMID:22581306.
   PubMed Web of Science ®Google Scholar
• Olioso P, Giancola R, Di Riti M, Contento A, Accorsi P, Iacone A. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol. 2009;27:130–9. doi:10.1002/hon.886. PMID:19294626.
   PubMed Web of Science ®Google Scholar
• Nishimura R, Baker J, Beilhack A, Zeiser R, Olson JA, Sega EI, Karimi M, Negrin RS. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood. 2008;112:2563–74. doi:10.1182/blood-2007-06-092817. PMID:18565854.
   PubMed Web of Science ®Google Scholar
• Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, Lassailly F, Tettamanti S, Spinelli O, Biondi A, Biagi E, Bonnet D. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia. 2014;28:1596–605. doi:10.1038/leu.2014.62. PMID:24504024.
   PubMed Web of Science ®Google Scholar
• Tettamanti S, Marin V, Pizzitola I, Magnani CF, Giordano Attianese GM, Cribioli E, Maltese F, Galimberti S, Lopez AF, Biondi A, et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol. 2013;161:389–401. doi:10.1111/bjh.12282. PMID:23432359.
   PubMed Web of Science ®Google Scholar
• Hombach AA, Rappl G, Abken H. Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 “super-stimulation”. Mol Ther. 2013;21:2268–77. doi:10.1038/mt.2013.192. PMID:23985696.
   PubMed Web of Science ®Google Scholar
• Oelsner S, Wagner J, Friede ME, Pfirrmann V, Genßler S, Rettinger E, Buchholz CJ, Pfeifer H, Schubert R, Ottmann OG, et al. CAR-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-ALL and enhance survival. Int J Cancer. 2016;139(8):1799–809. doi:10.1002/ijc.30217. PMID:27253354.
   PubMed Web of Science ®Google Scholar
• Zuo S, Wen Y, Panha H, Dai G, Wang L, Ren X, Fu K. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers. Mol Immunol. 2017;85:293–304. doi:10.1016/j.molimm.2017.03.017. PMID:28360017.
   PubMed Web of Science ®Google Scholar
• Guo X, Zheng H, Luo W, Zhang Q, Liu J, Yao K. 5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells. Sci Rep. 2017;7:4859. doi:10.1038/s41598-017-04756-9. PMID:28687750.
   PubMed Web of Science ®Google Scholar
• Zöller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 2011;11:254–67. doi:10.1038/nrc3023. PMID:21390059.
   PubMed Web of Science ®Google Scholar
• Casucci M, Nicolis di Robilant B, Falcone L, Camisa B, Norelli M, Genovese P, Gentner B, Gullotta F, Ponzoni M, Bernardi M, et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood. 2013;122:3461–72. doi:10.1182/blood-2013-04-493361. PMID:24016461.
   PubMed Web of Science ®Google Scholar
• Kuryu M, Ozaki T, Nishida K, Shibahara M, Kawai A, Inoue H. Expression of CD44 variants in osteosarcoma. J Cancer Res Clin Oncol 1999;125:646–52. doi:10.1007/s004320050329. PMID:10541973.
   PubMed Web of Science ®Google Scholar
• Gammaitoni L, Giraudo L, Macagno M, Leuci V, Mesiano G, Rotolo R, Sassi F, Sanlorenzo M, Zaccagna A, Pisacane A, et al. Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells. Clin Cancer Res. 2017;23(9):2277–88. doi:10.1158/1078-0432.CCR-16-1524. PMID:27815354.
   PubMed Web of Science ®Google Scholar
• Marin V, Kakuda H, Dander E, Imai C, Campana D, Biondi A, D'Amico G. Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal. Exp Hematol. 2007;35:1388–97. doi:10.1016/j.exphem.2007.05.018. PMID:17656004.
   PubMed Web of Science ®Google Scholar
• Ren X, Ma W, Lu H, Yuan L, An L, Wang X, Cheng G, Zuo S. Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor (EGFR)-positive malignancies. Cancer Immunol Immunother. 2015;64:1517–29. doi:10.1007/s00262-015-1757-6. PMID:26386966.
   PubMed Web of Science ®Google Scholar
• Huang X, Park H, Greene J, Pao J, Mulvey E, Zhou SX, Albert CM, Moy F, Sachdev D, Yee D, et al. IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas. PLoS One. 2015;10:e0133152. doi:10.1371/journal.pone.0133152. PMID:26173023.
   PubMed Web of Science ®Google Scholar
• Schönfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, Bönig H, Köhl U, Kloess S, et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther. 2015;23:330–8. doi:10.1038/mt.2014.219. PMID:25373520.
   PubMed Web of Science ®Google Scholar
• Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy. 2008;10:625–32. doi:10.1080/14653240802301872. PMID:18836917.
   PubMed Web of Science ®Google Scholar
• Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U, et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy. 2013;15:1563–70. doi:10.1016/j.jcyt.2013.06.017. PMID:24094496.
   PubMed Web of Science ®Google Scholar
• Gauthier J, Yakoub-Agha I. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives. Curr Res Transl Med. 2017;65:93–102. doi:10.1016/j.retram.2017.08.003. PMID:28988742.
   PubMed Web of Science ®Google Scholar
• Maus MV, Levine BL. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist. Oncologist. 2016;21:608–17. doi:10.1634/theoncologist.2015-0421. PMID:27009942.
   PubMed Web of Science ®Google Scholar
• Suzuki A, Leland P, Joshi BH, Puri RK. Targeting of IL-4 and IL-13 receptors for cancer therapy. Cytokine. 2015;75:79–88. doi:10.1016/j.cyto.2015.05.026. PMID:26088753.
   PubMed Web of Science ®Google Scholar
• Spear P, Barber A, Rynda-Apple A, Sentman CL. Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF. J Immunol. 2012;188:6389–98. doi:10.4049/jimmunol.1103019. PMID:22586039.
   PubMed Web of Science ®Google Scholar
• Toi M, Bicknell R, Harris AL. Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res 1992;52:275–9. PMID:1728401.
   PubMed Web of Science ®Google Scholar
• Börjesson PK, Postema EJ, Roos JC, Colnot DR, Marres HA, van Schie MH, Stehle G, de Bree R, Snow GB, Oyen WJ, et al. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2003;9:3961. S-72S.
   PubMed Web of Science ®Google Scholar
• Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006;12:6064–72. doi:10.1158/1078-0432.CCR-06-0910. PMID:17062682.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ding C, Wang J, Sun G, Cao Y, Xu L, Zhou L, Chen X. Prognostic significance of CD44V6 expression in osteosarcoma: a meta-analysis. J Orthop Surg Res. 2015;10:187. doi:10.1186/s13018-015-0328-z. PMID:26697855.
   PubMed Web of Science ®Google Scholar
• Irsan I, Akisue T, Hara H, Fujimoto T, Imabori M, Doita M, Kuroda R, Fujioka H, Kawamoto T, Yamamoto T, et al. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo. Anticancer Res. 2007;27:423–9. PMID:17352263.
   PubMed Web of Science ®Google Scholar
• Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 2010;70:2235–44. doi:10.1158/0008-5472.CAN-09-2335. PMID:20215499.
   PubMed Web of Science ®Google Scholar
• Fernández L, Metais JY, Escudero A, Vela M, Valentín J, Vallcorba I, Leivas A, Torres J, Valeri A, Patiño-García A, et al. MEMORY T CELLS EXPRESSING AN NKG2D-CAR EFFICIENTLY TARGET OSTEOSARCOMA CELLS. Clin Cancer Res. 2017;23(19):5824–35. doi:10.1158/1078-0432.CCR-17-0075.
   Web of Science ®Google Scholar